Abstract
We administered 1-benzyl-1,2,3,4-tetrahydroisoquinoline (1-BnTIQ; 80 mg/kg, i.p.), an endogenous neurotoxin known to cause bradykinesia, the Parkinson's disease-like symptom, in order to obtain biochemical and pathological evidence of behavioral abnormalities. Immunohistochemical analysis demonstrated that 1-BnTIQ did not decrease the number of tyrosine hydroxylase-positive cells in the substantia nigra. Biochemical analysis demonstrated significantly increased striatal dopamine (DA) content, while DA metabolites in the striatum remained at control levels. We concluded that the 1-BnTIQ-induced bradykinesia has a different mechanism of action than that underlying the MPTP-induced depletion of striatal DA neurons.
MeSH terms
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / administration & dosage
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacology
-
3,4-Dihydroxyphenylacetic Acid / metabolism
-
Animals
-
Dopamine / analogs & derivatives*
-
Dopamine / metabolism
-
Drug Administration Schedule
-
Homovanillic Acid / metabolism
-
Hydroxyindoleacetic Acid / metabolism
-
Isoquinolines / administration & dosage
-
Isoquinolines / toxicity*
-
Male
-
Mice
-
Mice, Inbred C57BL
-
Nerve Tissue Proteins / analysis
-
Parkinson Disease / metabolism
-
Parkinson Disease / pathology
-
Parkinson Disease, Secondary / chemically induced*
-
Serotonin / metabolism
-
Substantia Nigra / drug effects*
-
Substantia Nigra / metabolism
-
Substantia Nigra / pathology
-
Tetrahydroisoquinolines*
-
Tyrosine 3-Monooxygenase / analysis
Substances
-
Isoquinolines
-
Nerve Tissue Proteins
-
Tetrahydroisoquinolines
-
3,4-Dihydroxyphenylacetic Acid
-
Serotonin
-
Hydroxyindoleacetic Acid
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
-
Tyrosine 3-Monooxygenase
-
3-methoxytyramine
-
Dopamine
-
1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline
-
Homovanillic Acid